postsynaptic forebrain hyperactivity downstream of SSRI treatment may play a role in SSRI resistance in MDD (Molecular Psychiatry, 2019-1-30)

https://www.nature.com/articles/s41380-019-0363-y

http://alert.psychnews.org/ (Psychiatry News Alert, 2019-2-5)